DLGAP5 and hepatocellular carcinoma: Moreover, DLGAP5 promotes the proliferation and invasion of hepatocellular carcinoma (HCC) (Tang et al., 2021), bladder cancer (BLCA) (Zhou et al., 2024), and breast cancer (Li et al., 2023).